Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer drug shows promise in Long-Term study

NCT ID NCT06752941

Disease control Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study follows 36 Italian patients with Polycythemia Vera who responded well to Ropeginterferon alfa-2b in an earlier trial. Researchers will check every 6 months whether the treatment continues to keep their red blood cell levels normal and prevent the disease from getting worse. The goal is to see if long-term use of this drug can maintain control of the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ropeginterferon alfa-2b
What this could lead to
If successful, this study could show that long-term use of Ropeginterferon alfa-2b helps keep Polycythemia Vera under control without disease progression.
What could go wrong
This is an observational study with no control group, so it cannot prove cause and effect. Results may not apply to all patients, and long-term side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

36 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Thirty-six patients completed the Low-PV RCT and were still under treatment with Ropeg at study end. The "LOW-PV Continuation" study aim to update data of all these patients, regardless of the treatment they are undergoing at the time of enrollment in the current study, after having obtained their informed consent to participation.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients enrolled in the LOW-PV RCT study who continued to receive Ropeginterferon alfa-2b until the conclusion of the study on March 31, 2023. These patients will be included regardless of the treatment they are undergoing at the time of enrollment in the current study. * Patients who have signed the written informed consent for study participation. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycythemia vera are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycythemia vera

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U

    Torino, 10126, Italy

  • ASST Papa Giovanni XXIII, SC Ematologia

    Bergamo, Italy

  • ASST Sette Laghi, Ospedale di Circolo e F. Macchi, Divisione UO Ematologia

    Varese, Italy

  • Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo

    Naples, 80131, Italy

  • Azienda Ospedaliero Universitaria Careggi, SOD Ematologia

    Florence, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia

    Novara, 28100, Italy

  • Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia

    Vicenza, Italy

  • Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, SC Ematologia

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo, Divisione Ematologia

    Pavia, Lombardy, 27100, Italy

  • Ospedale Borgo Roma, Divisione Ematologia

    Verona, Veneto, 37134, Italy

  • Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo

    Milan, Italy

  • Policlinico S. Orsola - Malpighi, UO Ematologia

    Bologna, Italy

  • Policlinico Universitario Fondazione Agostino Gemelli

    Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.